| Description | Xinidamine (BRN 0891979) has antitumor activity and can be used to study benign prostatic hyperplasia, macular degeneration and prostatic intraepithelial neoplasia .Xinidamine inhibits the proliferation of PWR-1E cells with an IC50 of 4 μM. |
| Target activity | Proliferation (PWR-1E cells):4 μM |
| Synonyms | BRN 0891979, Xinidaminum, Xinidamino |
| molecular weight | 280.32 |
| Molecular formula | C17H16N2O2 |
| CAS | 50264-78-3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 50 mg/mL (178.37 mM) |
| References | 1. Chen H, et al. Effective platinum(IV) prodrugs conjugated with lonidamine as a functional group working on the mitochondria. J Inorg Biochem. 2018;180:119-128. 2. Cohen-Erez I, et al. Negatively charged polypeptide-peptide nanoparticles showing efficient drug delivery to the mitochondria. Colloids Surf B Biointerfaces. 2018;162:186-192. 3. Liu Y, et al. Mitochondrial-Targeting Lonidamine-Doxorubicin Nanoparticles for Synergistic Chemotherapy to Conquer Drug Resistance. ACS Appl Mater Interfaces. 2017;9(50):43498-43507. 4. Albatany M, et al. Dichloroacetate induced intracellular acidification in glioblastoma: in vivo detection using AACID-CEST MRI at 9.4 Tesla. J Neurooncol. 2018;136(2):255-262. |